



**Knut Sverre Skurdal Andresen**

Partner, Oslo

[knut.andresen@schjodt.com](mailto:knut.andresen@schjodt.com)

M: +47 951 74 153

T: +47 23 01 15 45

Knut Sverre is working with litigation in the ordinary courts and with dispute resolution in international and national arbitration. He specialises in IP dispute resolution, and works particularly with patent disputes concerning pharmaceutical, fishing, transportation and offshore technology, as well as trademark, copyright, unfair competition and marketing law disputes, and IT disputes. Knut Sverre also advises clients in cutting edge technology development projects and technology/IP M&A, and is considered a preferred strategic advisor in commercial IP and licensing matters. He has been involved in some of the most significant patent disputes before Norwegian courts in recent time. He also has broad experience from disputes concerning various commercial law matters.

Knut Sverre appears regularly as a seminar speaker and lecturer on various IP and civil procedural issues. He is author of The Legal 500 Intellectual Property Comparative Legal Guide Norway, Chambers Patent Litigation Practice for Norway and co-author of the online annotated Norwegian Civil Procedure Act.

In 2020, Knut Sverre wrote the Chambers Global Practice Guide: Patent Litigation Norway. Read the publication [here](#). Also in 2020, Knut Sverre wrote the Legal 500 Intellectual Property Comparative Legal Guide Norway. Read the publication [here](#).

---

## Practice areas

---

- Data Protection & Privacy
- Digital Innovation & TMT
- Dispute Resolution
- Fisheries & Aquaculture
- Intellectual Property
- Life Sciences
- Litigation & Arbitration
- Media & Entertainment
- Mining & Minerals
- Oil & Gas
- Trade & Industry

---

## About Knut Sverre

---

### Experience

**Attorney in charge** of several patent validity and infringement cases

**Attorney in charge** of several trademark law, unfair competition law and marketing law cases

**Attorney in charge** of SCC arbitrations concerning i.a. product design and offshore technology

**Attorney in charge** for more than 150 arbitration and litigation cases concerning IP, licencing, contract law and agency law

**Attorney in charge** of several cutting edge technology development projects, e.g. concerning MedTech, AI technology, autonomous driving, and transportation infrastructure

### Rankings

**2021** Next Generation Partners, Recommended and Other key lawyer - Legal 500

**2020** Recommended - Legal 500: 'Knut Sverre Skurdal Andersen is analytical and provides well thought through advice. As a client, you can trust that he always has taken the full perspective and next step into account.'

**2020** Knut Sverre Skurdal Andresen "thrives when untangling knotty disputes in the pharmaceutical sector", WTR 1000

**2019** "Rising Star" - Managing Intellectual Property IP Stars

**2018** "Rising Star" - Managing Intellectual Property IP Stars

### Education

**2008** Master of Law, University of Oslo

**2001** Cambridge Syndicate Examination in Business Leadership, University of Cambridge

---

## Publications

---

**2020** Chambers Global Practice Guide: Patent Litigation Norway

**2020** The Legal 500 Intellectual Property Comparative Legal Guide Norway

**2019** Gyldendal Rettsdata, Commentary to the Norwegian Civil Procedure Act chapters 10, 20, 29, 30 and 31

**2009** Obiter dicta as a source of law - a question of the role of the Courts of Justice. Changes in the Norwegian Supreme Court's argumentation in the time of internationalisation? Centre for European Law

**2009** EuroRett nr. 1 2008 – nr. 1. 2009, Centre for European Law/Lovdata

---

## References

---

- Acted for Merck Sharp & Dohme in a multi-jurisdictional pharmaceutical patent and SPC infringement case concerning a pharmaceutical combination product comprising ezetimibe and simvastatin
- Acted for one of Norway's largest suppliers of pharmaceuticals and health-related products in a litigation concerning purchase of shares in an independent pharmacy
- Acted for a Norwegian client concerning biotechnology before the ordinary courts and The European Court of Human Rights
- Acted for Norwegian company in several matters, i.a. transfer and novation of an infrastructure agreement worth NOK 10 billion, execution and implementation of the railroad reform and procurement of new rolling stock for the Norwegian railroads
- Acted for Gilead in Norway's most significant pharmaceutical patent case, concerning validity of patents for treatment of hepatitis C with sofosbuvir